Molecular Function – Page 3

Novartis’ Scemblix Demonstrates Superior Efficacy and Safety in Newly Diagnosed Leukemia Patients ###

1 year ago talkbio0Tagged Clinical Oncology ( ASCO, Gleevec, leukemia, Myeloid Leukemia, Chronic, Novartis, Scemblix, Tyrosine Kinase Inhibitors [MoA]

Novartis, Scemblix, Leukemia, Chronic Myeloid Leukemia (CML), Tyrosine Kinase Inhibitors (TKIs), Gleevec, American Society of Clinical Oncology (ASCO)

Biotech Roundup: Compugen, Nxera Milestone Payments; Insmed Seeks $650M Offering

1 year ago talkbio0Tagged AstraZeneca, Bio, BMS, Breyanzi, Burning Mouth Syndrome, Celcuity, Compugen, K-ras Oncogene, luteolin-7-O-diglucuronide 4'-O-glucuronosyltransferase activity, milestone payments, Nordisk, Novartis, Nxera, United States Food and Drug Administration

Compugen, Nxera, milestone payments, Insmed, $650M offering, biotech, pharmaceuticals, Celcuity, Weave Bio, AstraZeneca, Novo Nordisk Foundation, FDA, LDT rule, BMS, Breyanzi, KRAS drug, Novartis

Takeda Ventures into Molecular Glue Degraders with Degron Collaboration

1 year ago talkbio0Tagged Degron, Drug Discovery, molecular glue, pharmaceutical collaboration, Protein Degradation, Metabolic, Takeda

Takeda, Degron, molecular glue degraders, pharmaceutical collaboration, targeted protein degradation, drug discovery.

Intellectual property landscape around prime editing

1 year ago talkbio0Tagged CRISPR, Patent infringement, patent litigation, Prime Editing

Intellectual Property Landscape Around Prime Editing Prime editing, a revolutionary genome editing technology, has been at the forefront of significant intellectual property developments and patent disputes. This technology, which allows for precise DNA edits without the need for double-strand breaks, was developed by Dr. David Liu and his team at the Broad Institute and Harvard […]

Enlaza Secures $100M for Groundbreaking Irreversible Protein Binding Technology

1 year ago talkbio0Tagged Biotechnology, Drug Development, Enlaza, Investments, irreversible, Medical Research activity, Protein Binding

Enlaza, funding, investment, protein binding, irreversible, biotechnology, medical research, drug development, therapeutics.

Enhanced Optimization for Influenza B Strains Planned in CureVac’s mRNA Seasonal Flu Vaccine Trials

1 year ago talkbio0Tagged cellular targeting, Collaboration, CureVac, Immune response, Improved, influenza B strains, mRNA flu, Optimization, Vaccines

CureVac, mRNA flu vaccine, Influenza B strains, Targeted optimization, Phase 2 studies, Multivalent candidate, Improved immune response, Collaboration with GSK